[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638533":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":25,"locations":31,"responsibleParty":61,"collaborators":12,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":12,"enrollmentInfo":74,"targetDuration":12,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":87,"whyStopped":12,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Unidade Local de Saude do Nordeste","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Conventional therapy","NO_INTERVENTION","Conventional therapy to ACLF",null,{"label":14,"type":15,"description":16,"interventionNames":17},"DPMAS plus Plasma exchange","EXPERIMENTAL","Patients in this arm will be submitted to:\n\nDPMAS: selective adsorption therapy; mainly removes bilirrubin and inflammatory mediators AND Half-dose plasma exchange: nonselective plasma removal and replacement by a donor",[18],"Device: DPMAS plus plasma exchange",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DEVICE","DPMAS plus plasma exchange","Use of extracorporal technique to support patients with acute on chronic liver failure",[14],[26],{"name":27,"role":28,"phone":29,"phoneExt":12,"email":30},"Tiago B Loza, Graduated Physician","CONTACT","00351 913013068","tiago.loza@ulsne.min-saude.pt",[32],{"facility":33,"status":12,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Unidade Hospitalar de Bragança","Bragança","Braganza District","5301-852","Portugal","PT",{"type":40,"coordinates":41},"Point",[42,43],-6.75898,41.80716,{"lat":43,"lon":42},[46,50,53,55,57,59],{"name":47,"role":28,"phone":48,"phoneExt":49,"email":30},"Tiago B Loza, Consultant Physician","913013068","00351",{"name":51,"role":52,"phone":12,"phoneExt":12,"email":12},"Carla Gomes","SUB_INVESTIGATOR",{"name":54,"role":52,"phone":12,"phoneExt":12,"email":12},"Antonio Grilo Novais",{"name":56,"role":52,"phone":12,"phoneExt":12,"email":12},"Carla Pires",{"name":58,"role":52,"phone":12,"phoneExt":12,"email":12},"Raquel Leitão",{"name":60,"role":52,"phone":12,"phoneExt":12,"email":12},"Tiago Ceriz",{"type":62,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"PRINCIPAL_INVESTIGATOR","Tiago Bessa Gradim Loza","Main investigator","100638533","plasma-exchange-half-dose-and-extracorporeal-detoxification-for-aclf-100638533",false,"NCT07593638","Plasma Exchange Half-dose and Extracorporeal Detoxification for ACLF","Phoenix","Inclusion Criteria:\n\n* Written informed consent for participation in the study\n* Admission to the ICU with a diagnosis of ACLF of reversible etiology (infection, bleeding, alcohol-related, toxic, etc.)\n* Total bilirubin ≥ 12 mg\u002FdL and INR ≥ 1.5\n* On the waiting list for liver transplantation or not a candidate for transplantation but with an indication for supportive therapy\n\nExclusion Criteria:\n\n* Refusal to provide consent\n* Pregnancy\n* Expected survival \\\u003C 24 hours due to disease severity (hemodynamic instability requiring norepinephrine \\> 0.20 mcg\u002Fkg\u002Fmin and\u002For mechanical ventilation with PaO₂\u002FFiO₂ \\\u003C 150 and\u002For non-hepatic coma)\n* ACLF severity greater than CLIF-C ACLF grade 3\n* Advanced organ dysfunction: Pulmonary (GOLD stage 3 or 4) and\u002For Cardiac (NYHA functional class III or IV)\n* Advanced or metastatic oncological disease (life expectancy \\\u003C 6 months)\n* Marked frailty syndrome or secondary sarcopenia\n* Participation in another clinical trial within the previous 3 months","ALL","18 Years",{"count":75,"type":76},240,"ESTIMATED","INTERVENTIONAL",[79],"NA","Clinical trial\n\nThe goal of this clinical trial is to learn if a liver support protocol works to treat Liver failure in adults. The main questions it aims to answer are:\n\n* Does hemoadsorption plus half-dose plasma exchange provide support to liver failure patients until recovery or transplant\n* What medical problems do participants have during the technique? Researchers will compare DPMAS plus half-dose plasma exchange with conventional treatment to evaluate a gain in recovery\n\nParticipants will:\n\n* Be submitted to DPMAS plus half dose plasma exchange daily according to protocol.\n* Monitoring will be continuous in the ICU",[82],"Acute on Chronic Liver Failure (ACLF)",[84,85,86],"DPMAS","Plasma exchange","ACLF","NOT_YET_RECRUITING","2026-05-11",{"date":90,"type":91},"2026-05-18","ACTUAL",{"date":93,"type":76},"2026-07",{"date":95,"type":76},"2028-01",{"name":5,"class":6},1]